As we close the chapter on 2025, and with just over a year to go before the IRCM 60th anniversary, one thing is clear: IRCM is moving forward, fast and strong! This year was marked by scientific breakthroughs, prestigious distinctions, and bold projects that confirm our role as a leader in biomedical research.
Highlights We’re Proud of:
- Cancer immunotherapy: Advances made possible by our monoclonal antibody production platform, a cutting-edge tool driving research toward new therapeutic solutions.
- A Therapeutic RNA platform: Funded, deployed, and already in action! Supporting concrete projects and building strategic bridges with industry.
- Two start-ups born from our research: Proof that innovation at IRCM doesn’t stop in the lab; it transforms into tangible solutions for society.
These achievements add to major discoveries, awards and distinctions for our researchers and trainees, and even the FDA approval of a treatment for a rare genetic disease co-discovered here at the IRCM. All are milestones that illustrate our ambition which is to understand life to propel innovative therapies.
Of course, challenges remain: an uncertain economic climate, funding issues for research and care, global competition for visibility and resources, and digital transformation. But our response is unwavering: anchored in core values and powered by boldness, creativity, and resilience. We don’t just ride the wave, we anticipate it, master it, and we’re never afraid to get wet.
|
2025 in Numbers |
As 2026 begins, with an institute strengthened by decades of excellence, we are proud of the path we’ve travelled and ready for what’s to come. Thank you to our partners, collaborators, and friends for their trust and support. Together, we will continue to push the boundaries of science and deliver exceptional care.
May the new year bring health, inspiration, and success. Together, everything is possible!
